Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression - PubMed (original) (raw)

. 2000 Apr 1;60(7):2002-6.

Affiliations

PMID: 10766191

Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression

R E Wilentz et al. Cancer Res. 2000.

Abstract

Infiltrating adenocarcinomas of the pancreas are believed to arise from histologically identifiable intraductal precursors [pancreatic intraepithelial neoplasias (PanINs)] that undergo a series of architectural, cytological, and genetic changes. The role of DPC4 tumor suppressor gene inactivation in this progression has not been defined. Immunohistochemistry for the Dpc4 protein in formalin-fixed, paraffin-embedded tissue is a sensitive and specific marker for DPC4 gene status, providing a tool to examine DPC4 status in these putative precursor lesions. A total of 188 PanINs were identified in 40 pancreata, 38 (95%) of which also contained an infiltrating adenocarcinoma. Sections containing these 188 duct lesions were labeled with a monoclonal antibody to Dpc4. All 82 flat (PanIN-1A), all 54 papillary (PanIN-1B), and all 23 atypical papillary (PanIN-2) intraductal lesions expressed Dpc4. In contrast, 9 of 29 (31%) severely atypical lesions (PanIN-3 lesions, carcinomas in situ) did not. The difference in Dpc4 expression between histologically low-grade (PanIN-1 and -2) and histologically high-grade (PanIN-3) duct lesions was statistically significant (P < 0.0001). In three cases, the pattern of Dpc4 expression in the PanIN-3 lesions did not match the pattern of expression in the associated infiltrating carcinomas, indicating that these high-grade lesions did not simply represent infiltrating carcinoma growing along benign ducts. Loss of Dpc4 expression occurs biologically late in the neoplastic progression that leads to the development of infiltrating pancreatic cancer, at the stage of histologically recognizable carcinoma.

PubMed Disclaimer

Cited by

PanIN-specific regulation of Wnt signaling by HIF2α during early pancreatic tumorigenesis.
Criscimanna A, Duan LJ, Rhodes JA, Fendrich V, Wickline E, Hartman DJ, Monga SP, Lotze MT, Gittes GK, Fong GH, Esni F. Criscimanna A, et al. Cancer Res. 2013 Aug 1;73(15):4781-90. doi: 10.1158/0008-5472.CAN-13-0566. Epub 2013 Jun 7. Cancer Res. 2013. PMID: 23749643 Free PMC article.
Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma.
Sagami R, Yamao K, Nakahodo J, Minami R, Tsurusaki M, Murakami K, Amano Y. Sagami R, et al. Cancers (Basel). 2021 Feb 24;13(5):945. doi: 10.3390/cancers13050945. Cancers (Basel). 2021. PMID: 33668239 Free PMC article. Review.
Pancreatic cancer genomics: insights and opportunities for clinical translation.
Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Makohon-Moore A, et al. Genome Med. 2013 Mar 28;5(3):26. doi: 10.1186/gm430. eCollection 2013. Genome Med. 2013. PMID: 23673020 Free PMC article. Review.
Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells.
Wan R, Feng J, Tang L. Wan R, et al. Onco Targets Ther. 2021 Apr 13;14:2531-2540. doi: 10.2147/OTT.S297855. eCollection 2021. Onco Targets Ther. 2021. PMID: 33888990 Free PMC article. Review.
Alterations of PTEN and SMAD4 methylation in diagnosis of breast cancer: implications of methyl II PCR assay.
Swellam M, Saad EA, Sabry S, Denewer A, Abdel Malak C, Abouzid A. Swellam M, et al. J Genet Eng Biotechnol. 2021 Apr 6;19(1):54. doi: 10.1186/s43141-021-00154-x. J Genet Eng Biotechnol. 2021. PMID: 33825073 Free PMC article.

Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression - PubMed (original) (raw)